DefEYE Secures Strategic Investment from ExSight Ventures to Advance Ocular Biologics Platform

DefEYE获得ExSight Ventures战略投资，以推进眼部生物制品平台的发展。

November 12, 2025

2025年11月12日

DefEYE, a developer of regenerative biologic technologies for ophthalmology, has announced an investment from ExSight Ventures to support the advancement and commercialization of its decellularized placental-based tissue platform. The technology is designed for use in ocular surface disease and ocular surgical management, including procedures such as pterygium surgery..

DefEYE是一家致力于开发眼科再生生物技术的公司，近日宣布获得ExSight Ventures的投资，以支持其基于脱细胞胎盘组织平台的技术进展和商业化。该技术旨在用于眼表疾病和眼部手术管理，包括翼状胬肉手术等手术程序。

According to the announcement, the platform aims to offer a portfolio of decellularized biologic solutions to enhance treatment outcomes across a range of anterior segment conditions.

根据公告，该平台旨在提供一系列去细胞化的生物解决方案，以改善各种前节疾病状况的治疗效果。

ExSight Ventures, an ophthalmology-focused investment firm, has characterized DefEYE’s biologic approach as an innovative entry into the ocular biologics space. Despite initial skepticism, the firm cited positive clinical feedback as a key factor in the decision to invest.

专注于眼科的投资公司ExSight Ventures认为，DefEYE的生物方法是进入眼部生物制品领域的一项创新。尽管最初存在疑虑，但该公司表示，积极的临床反馈是其决定投资的关键因素。

“ExSight’s investment defies our initial skepticism of the technology and the market,” said Firas Rahhal, cofounder at ExSight Ventures. “Feedback pointed to better clinical outcomes, improved patient experience, and consequently, growing adoption.”

“ExSight的投资打破了我们最初对技术和市场的怀疑，”ExSight Ventures的联合创始人Firas Rahhal表示。“反馈表明，临床结果更好，患者体验改善，因此，采用率也在不断增长。”

Strategic Partnership to Support Commercial Expansion

战略合作以支持商业扩张

DefEYE’s chief executive officer, Rob Sambursky, MD, emphasized the strategic alignment between the two companies:

DefEYE的首席执行官罗布·桑布尔斯基博士强调了两家公司之间的战略一致性：

“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE.”

“ExSight Ventures在眼科领域推动创新的深厚知识和长期承诺使他们成为DefEYE的理想战略合作伙伴。”

He added that the investment will help accelerate the adoption of regenerative therapies that aim to improve both ocular surface disease management and surgical outcomes.

他表示，这项投资将有助于加速推动旨在改善眼表疾病管理和手术结果的再生疗法的采用。

Terms of the Investment Remain Undisclosed

投资条款尚未披露

While the companies did not release specific financial terms, both parties confirmed that the funding will be directed toward commercial growth and platform expansion, reinforcing DefEYE’s position in the emerging field of ocular biologics.

虽然两家公司并未透露具体的财务条款，但双方都确认，这笔资金将用于商业增长和平台扩展，巩固DefEYE在新兴的眼部生物制品领域的地位。